Micrometastasis — Microscopic Cancer Spread

Micrometastasis is defined pathologically as an aggregate of malignant cells measuring between 0.2 millimetres and 2.0 millimetres in greatest diameter. These microscopic deposits have escaped the primary tumour via lymphatic channels or the vascular system and lodged in regional lymph nodes or distant tissues. Because of their tiny dimensions, they do not cause symptoms or form visible lesions on computed tomography, MRI, or PET scans.

In pathology staging, particularly within sentinel lymph node examinations, micrometastases are distinguished from isolated tumour cells (ITCs), which measure less than 0.2 millimetres, and macrometastases, which exceed 2.0 millimetres. Even though micrometastases are clinically silent at the time of discovery, they represent viable neoplastic cells that possess the potential to proliferate into macroscopic secondary tumours if not eliminated by adjuvant systemic therapy or immune mechanisms.

Discovering micrometastases provides critical prognostic information that guides post-surgical treatment plans. Even after a surgeon successfully removes all visible tumour tissue, invisible microscopic deposits could remain elsewhere in the body. Recognising the presence or high likelihood of micrometastases allows your oncology team to recommend adjuvant therapies tailored to destroy these residual cells. This preventative strategy significantly lowers the likelihood of cancer recurring months or years later. Understanding micrometastases helps patients see why systemic treatments are often advised even when all visible scans appear completely clear.

Micrometastases cannot be detected by conventional radiology scans like CT, MRI, or PET. Instead, they are identified pathologically through sentinel lymph node biopsies and microscopic tissue evaluation. Pathologists use serial sectioning and immunohistochemistry (IHC) staining—often targeting cytokeratins or melanocytic markers—to highlight tiny clusters of cancer cells measuring 0.2 to 2.0 millimetres. Emerging techniques such as liquid biopsy, which detects circulating tumour DNA (ctDNA) or circulating tumour cells in peripheral blood, are increasingly investigated to identify molecular residual disease representing occult micrometastases.

Micrometastasis is most commonly evaluated in breast cancer, cutaneous melanoma, and gastrointestinal cancers, notably colorectal and gastric malignancies. In breast cancer and melanoma, sentinel lymph node biopsies are routinely performed specifically to search for micrometastatic deposits that dictate staging. Micrometastases also play a significant role in staging prostate, gynaecological (such as cervical and endometrial), and lung cancers, where microscopic nodal involvement or occult dissemination significantly alters recurrence risk assessments and influences choices regarding post-operative adjuvant therapy.

Because micrometastases represent occult or microscopic spread, their presence directly drives recommendations for adjuvant systemic therapy after primary surgery. Treatment strategies include adjuvant chemotherapy, targeted molecular agents, immune checkpoint inhibitors, or endocrine therapy intended to eradicate microscopic disease throughout the body. In some cancers, the presence of micrometastases in sentinel lymph nodes may also guide decisions about whether completion lymph node dissection or regional nodal radiation therapy is necessary to achieve durable disease control and minimise local-regional recurrence.